GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangdong Hybribio Biotech Co Ltd (SZSE:300639) » Definitions » Forward PE Ratio

Guangdong Hybribio Biotech Co (SZSE:300639) Forward PE Ratio : 0.00 (As of May. 21, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Guangdong Hybribio Biotech Co Forward PE Ratio?

Guangdong Hybribio Biotech Co's Forward PE Ratio for today is 0.00.

Guangdong Hybribio Biotech Co's PE Ratio without NRI for today is 60.00.

Guangdong Hybribio Biotech Co's PE Ratio for today is 45.80.


Guangdong Hybribio Biotech Co Forward PE Ratio Historical Data

The historical data trend for Guangdong Hybribio Biotech Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangdong Hybribio Biotech Co Forward PE Ratio Chart

Guangdong Hybribio Biotech Co Annual Data
Trend
Forward PE Ratio

Guangdong Hybribio Biotech Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Guangdong Hybribio Biotech Co's Forward PE Ratio

For the Diagnostics & Research subindustry, Guangdong Hybribio Biotech Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangdong Hybribio Biotech Co's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guangdong Hybribio Biotech Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Guangdong Hybribio Biotech Co's Forward PE Ratio falls into.



Guangdong Hybribio Biotech Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Guangdong Hybribio Biotech Co  (SZSE:300639) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Guangdong Hybribio Biotech Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Guangdong Hybribio Biotech Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Guangdong Hybribio Biotech Co (SZSE:300639) Business Description

Traded in Other Exchanges
N/A
Address
D 5-3-3-4, North High-tech Zone, Economic Development Zone, Chaozhou City, CHN, 521000
Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.

Guangdong Hybribio Biotech Co (SZSE:300639) Headlines

No Headlines